Multivariable analyses of hematopoietic recovery, fungal infection, transplantation-related mortality, and overall survival
| . | Hazard ratio (95% confidence interval) . | P . |
|---|---|---|
| Neutrophil engraftment | ||
| Female recipient | 1.72 (1.25-2.37) | .01 |
| CD34 ≥ 3.0 × 106/kg | 1.37 (1.01-1.85) | .04 |
| Secondary neutropenia | ||
| Advanced stage of disease | 2.12 (1.09-4.12) | .03 |
| Female recipient | 0.51 (0.28-0.94) | .03 |
| CD34 ≥ 3.0 × 106/kg | 0.60 (0.35-1.00) | .05 |
| Monocyte recovery | ||
| Female recipient | 1.46 (1.05-2.03) | .03 |
| CD34 ≥ 3.0 × 106/kg | 1.47 (1.07-2.03) | .02 |
| Lymphocyte recovery | ||
| Age of donor3-150 | 0.98 (0.97-1.00) | .01 |
| Positive CMV serology | 1.62 (1.15-2.28) | .006 |
| CD34 ≥ 3.0 × 106/kg | 1.70 (1.20-2.41) | .003 |
| Hemoglobin recovery | ||
| Chronic leukemia | 1.43 (1.05-1.96) | .02 |
| CD34 ≥ 3.0 × 106/kg | 1.77 (1.31-2.39) | .0002 |
| Gender match | 0.74 (0.55-0.98) | .04 |
| Platelet engraftment | ||
| Advanced stage of disease | 0.51 (0.30-0.86) | .01 |
| Female recipient | 1.37 (1.01-1.87) | .01 |
| CD34+ ≥ 3 × 106/kg | 1.98 (1.41-2.77) | .00008 |
| Invasive fungal infection | ||
| Advanced stage of disease | 2.49 (1.12-5.57) | .03 |
| CD34+ ≥ 3 × 106/kg | 0.41 (0.21-0.79) | .008 |
| Transplantation-related mortality | ||
| Age of recipient3-150 | 1.04 (1.02-1.06) | .0004 |
| Advanced stage of disease | 2.61 (1.37-4.98) | .0043-150 |
| Female donor | 0.52 (0.29-0.95) | .03 |
| CD34+ ≥ 3 × 106/kg | 0.54 (0.32-0.94) | .03 |
| Overall survival | ||
| Age of recipient3-150 | 1.03 (1.02-1.04) | .001 |
| Advanced stage of disease | 2.53 (1.60-4.25) | .0005 |
| Female | 0.57 (0.36-0.89) | .01 |
| CD34+ ≥ 3 × 106/kg | 0.55 (0.36-0.85) | .006 |
| . | Hazard ratio (95% confidence interval) . | P . |
|---|---|---|
| Neutrophil engraftment | ||
| Female recipient | 1.72 (1.25-2.37) | .01 |
| CD34 ≥ 3.0 × 106/kg | 1.37 (1.01-1.85) | .04 |
| Secondary neutropenia | ||
| Advanced stage of disease | 2.12 (1.09-4.12) | .03 |
| Female recipient | 0.51 (0.28-0.94) | .03 |
| CD34 ≥ 3.0 × 106/kg | 0.60 (0.35-1.00) | .05 |
| Monocyte recovery | ||
| Female recipient | 1.46 (1.05-2.03) | .03 |
| CD34 ≥ 3.0 × 106/kg | 1.47 (1.07-2.03) | .02 |
| Lymphocyte recovery | ||
| Age of donor3-150 | 0.98 (0.97-1.00) | .01 |
| Positive CMV serology | 1.62 (1.15-2.28) | .006 |
| CD34 ≥ 3.0 × 106/kg | 1.70 (1.20-2.41) | .003 |
| Hemoglobin recovery | ||
| Chronic leukemia | 1.43 (1.05-1.96) | .02 |
| CD34 ≥ 3.0 × 106/kg | 1.77 (1.31-2.39) | .0002 |
| Gender match | 0.74 (0.55-0.98) | .04 |
| Platelet engraftment | ||
| Advanced stage of disease | 0.51 (0.30-0.86) | .01 |
| Female recipient | 1.37 (1.01-1.87) | .01 |
| CD34+ ≥ 3 × 106/kg | 1.98 (1.41-2.77) | .00008 |
| Invasive fungal infection | ||
| Advanced stage of disease | 2.49 (1.12-5.57) | .03 |
| CD34+ ≥ 3 × 106/kg | 0.41 (0.21-0.79) | .008 |
| Transplantation-related mortality | ||
| Age of recipient3-150 | 1.04 (1.02-1.06) | .0004 |
| Advanced stage of disease | 2.61 (1.37-4.98) | .0043-150 |
| Female donor | 0.52 (0.29-0.95) | .03 |
| CD34+ ≥ 3 × 106/kg | 0.54 (0.32-0.94) | .03 |
| Overall survival | ||
| Age of recipient3-150 | 1.03 (1.02-1.04) | .001 |
| Advanced stage of disease | 2.53 (1.60-4.25) | .0005 |
| Female | 0.57 (0.36-0.89) | .01 |
| CD34+ ≥ 3 × 106/kg | 0.55 (0.36-0.85) | .006 |
CMV, cytomegalovirus.
Continuous variable.